RBC Capital Maintains a Buy on Boston Scientific Corporation (BSX) With a $125 PT

Boston Scientific Corporation (NYSE:BSX) is one of the best medical stocks to buy now. On September 29, RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Boston Scientific Corporation (NYSE:BSX) and set a price target of $125.00.

Boston Scientific Corporation (NYSE:BSX) reported in its fiscal Q2 2025 earnings that net sales for the quarter reached $5.061 billion, reflecting a 22.8% growth on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis, all compared to the prior year period.

The company also reported GAAP net income attributable to common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments.

The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.